Department of Pediatrics, University at Buffalo, Buffalo, NY, USA.
Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Vaccine. 2022 Jul 29;40(31):4174-4181. doi: 10.1016/j.vaccine.2022.05.083. Epub 2022 Jun 7.
In studies on monoclonal IgG antibodies (mAbs) from long-term non-progressors (LTNPs), our laboratory has previously described highly mutated Abs against a complex conformational epitope with contributions from both gp41 the N terminal and C terminal heptad repeat helices. Despite using the VH1-2 gene segment, known to contribute to some of the broadest neutralizing Abs against HIV, members of these Abs, termed group 76C Abs, did not exhibit broad neutralization. Because of the high number of mutations and use of VH1-2, our goal was to characterize the non-neutralizing functions of Abs of group 76C, to assess if targeting of the epitope correlates with LTNP, and to assess the maturation of these Abs by comparison to their predicted common ancestor. Serum competition assays showed group 76C Abs were enriched in LTNPs, in comparison to VRC-01. Specific group 76C clones 6F5 and 6F11, expressed as recombinant Abs, both have robust ADCC activity, despite their sequence disparity. Sequence analysis predicted the common ancestor of this clonal group would utilize the germline non-mutated variable gene. We produced a recombinant ancestor Ab (76Canc) with a heavy chain utilizing the germline variable gene sequence paired to the 6F5 light chain. Competition with group 76C recombinant Ab 6F5 confirms 76Canc binds HIV envelope constructs near the original group C epitope. 76Canc demonstrates comparable ADCC to 6F5 and 6F11 when using gp41 constructs of both clade B and clade C. The functional capability of Abs utilizing germline VH1-2 has implications for disease control and vaccine development.
在针对长期非进展者 (LTNP) 的单克隆 IgG 抗体 (mAb) 的研究中,我们实验室之前描述了针对具有 gp41 N 端和 C 端七肽重复螺旋贡献的复杂构象表位的高度突变抗体。尽管使用了已知有助于针对 HIV 产生一些最广泛中和抗体的 VH1-2 基因片段,但这些抗体的成员,称为 76C 组抗体,并没有表现出广泛的中和作用。由于突变数量多且使用 VH1-2,我们的目标是表征 76C 组抗体的非中和功能,评估针对该表位的靶向是否与 LTNP 相关,并通过与预测的共同祖先进行比较来评估这些抗体的成熟情况。血清竞争测定表明,与 VRC-01 相比,76C 组抗体在 LTNPs 中更为丰富。作为重组抗体表达的特异性 76C 克隆 6F5 和 6F11 均具有强大的 ADCC 活性,尽管它们的序列差异很大。序列分析预测,该克隆组的共同祖先将利用胚系未突变的可变基因。我们生产了一种重组祖先 Ab(76Canc),其重链利用胚系可变基因序列与 6F5 轻链配对。与 76C 组重组 Ab 6F5 的竞争证实 76Canc 结合 HIV 包膜构建体接近原始 C 组表位。当使用来自 clade B 和 clade C 的 gp41 构建体时,76Canc 显示出与 6F5 和 6F11 相当的 ADCC。利用胚系 VH1-2 的 Abs 的功能能力对疾病控制和疫苗开发具有重要意义。